JOP20180057A1 - مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 - Google Patents
مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6Info
- Publication number
- JOP20180057A1 JOP20180057A1 JOP/2018/0057A JOP20180057A JOP20180057A1 JO P20180057 A1 JOP20180057 A1 JO P20180057A1 JO P20180057 A JOP20180057 A JO P20180057A JO P20180057 A1 JOP20180057 A1 JO P20180057A1
- Authority
- JO
- Jordan
- Prior art keywords
- tetrahydropyridopyrazine
- gpr6
- modulators
- compound
- formula
- Prior art date
Links
- HOFCYSNYAFJTSI-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrido[2,3-b]pyrazine Chemical compound C1=CC=C2NCCNC2=N1 HOFCYSNYAFJTSI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762520430P | 2017-06-15 | 2017-06-15 | |
| US201762591247P | 2017-11-28 | 2017-11-28 | |
| US201862649856P | 2018-03-29 | 2018-03-29 | |
| US201862672261P | 2018-05-16 | 2018-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20180057A1 true JOP20180057A1 (ar) | 2019-01-30 |
Family
ID=64656005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2018/0057A JOP20180057A1 (ar) | 2017-06-15 | 2017-06-15 | مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10406157B2 (enExample) |
| EP (1) | EP3638673B9 (enExample) |
| JP (2) | JP7460369B2 (enExample) |
| KR (1) | KR102802861B1 (enExample) |
| CN (1) | CN110730781B (enExample) |
| AU (1) | AU2018285677B2 (enExample) |
| CA (1) | CA3067032A1 (enExample) |
| CO (1) | CO2019015086A2 (enExample) |
| DK (1) | DK3638673T3 (enExample) |
| ES (1) | ES2988680T3 (enExample) |
| FI (1) | FI3638673T3 (enExample) |
| HR (1) | HRP20241231T1 (enExample) |
| HU (1) | HUE068346T2 (enExample) |
| IL (1) | IL271332B2 (enExample) |
| JO (1) | JOP20180057A1 (enExample) |
| LT (1) | LT3638673T (enExample) |
| MX (1) | MX2019014940A (enExample) |
| PH (1) | PH12019502792A1 (enExample) |
| PL (1) | PL3638673T3 (enExample) |
| PT (1) | PT3638673T (enExample) |
| RS (1) | RS66018B1 (enExample) |
| SG (1) | SG11201912149WA (enExample) |
| SI (1) | SI3638673T1 (enExample) |
| TW (1) | TWI775874B (enExample) |
| WO (1) | WO2018232202A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026067262A1 (zh) * | 2024-09-26 | 2026-04-02 | 四川科伦药物研究院有限公司 | 并环化合物、包含其的药物组合物及其用途和方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US7229557B2 (en) | 2004-02-04 | 2007-06-12 | Konec, Inc. | Method to separate stereoisomers |
| WO2011005636A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Tetrahydronapthyridine orexin receptor antagonists |
| JO3466B1 (ar) | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
| UA117779C2 (uk) * | 2014-02-14 | 2018-09-25 | Такеда Фармасьютікал Компані Лімітед | Піразини як модулятори gpr6 |
| JP6526034B2 (ja) | 2014-02-14 | 2019-06-05 | 武田薬品工業株式会社 | Ｇｐｒ６のピリドピラジンモジュレーター |
-
2017
- 2017-06-15 JO JOP/2018/0057A patent/JOP20180057A1/ar unknown
-
2018
- 2018-06-15 LT LTEPPCT/US2018/037687T patent/LT3638673T/lt unknown
- 2018-06-15 JP JP2019563277A patent/JP7460369B2/ja active Active
- 2018-06-15 TW TW107120685A patent/TWI775874B/zh active
- 2018-06-15 HR HRP20241231TT patent/HRP20241231T1/hr unknown
- 2018-06-15 SI SI201831159T patent/SI3638673T1/sl unknown
- 2018-06-15 KR KR1020197037207A patent/KR102802861B1/ko active Active
- 2018-06-15 MX MX2019014940A patent/MX2019014940A/es unknown
- 2018-06-15 DK DK18818829.6T patent/DK3638673T3/da active
- 2018-06-15 WO PCT/US2018/037687 patent/WO2018232202A1/en not_active Ceased
- 2018-06-15 CN CN201880038831.4A patent/CN110730781B/zh active Active
- 2018-06-15 ES ES18818829T patent/ES2988680T3/es active Active
- 2018-06-15 PT PT188188296T patent/PT3638673T/pt unknown
- 2018-06-15 EP EP18818829.6A patent/EP3638673B9/en active Active
- 2018-06-15 RS RS20241067A patent/RS66018B1/sr unknown
- 2018-06-15 CA CA3067032A patent/CA3067032A1/en active Pending
- 2018-06-15 HU HUE18818829A patent/HUE068346T2/hu unknown
- 2018-06-15 AU AU2018285677A patent/AU2018285677B2/en active Active
- 2018-06-15 US US16/009,308 patent/US10406157B2/en active Active
- 2018-06-15 FI FIEP18818829.6T patent/FI3638673T3/fi active
- 2018-06-15 PL PL18818829.6T patent/PL3638673T3/pl unknown
- 2018-06-15 SG SG11201912149WA patent/SG11201912149WA/en unknown
-
2019
- 2019-12-10 PH PH12019502792A patent/PH12019502792A1/en unknown
- 2019-12-11 IL IL271332A patent/IL271332B2/en unknown
- 2019-12-30 CO CONC2019/0015086A patent/CO2019015086A2/es unknown
-
2022
- 2022-10-05 JP JP2022160819A patent/JP7497400B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| EP4365179A3 (en) | Novel rapamycin derivatives | |
| MX2021007432A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
| PH12018501068A1 (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX2020006459A (es) | Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar. | |
| NZ747259A (en) | Soluble c5ar antagonists | |
| MX2017011951A (es) | Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso. | |
| EP4609866A3 (en) | Oxysterols and methods of use thereof | |
| ZA201907746B (en) | 6-5 fused rings as c5a inhibitors | |
| SA520411843B1 (ar) | Trpc6 مشتقات بيريدين كربونيل والاستخدام الطبي لها كمثبطات | |
| AU2018253590A1 (en) | Imidazopyridazine compounds | |
| MD20160105A2 (ro) | 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide | |
| EP4316591A3 (en) | Oxysterols and methods of use thereof | |
| EP4599887A8 (en) | Oxysterols and methods of use thereof | |
| NZ759295A (en) | 5-5 fused rings as c5a inhibitors | |
| PH12017500841A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| EA201791802A1 (ru) | СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| SG10201806809QA (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| ZA202107777B (en) | Voruciclib polymorphs and methods of making and using thereof | |
| MX2023010303A (es) | Metodo de modulacion de las vias de se?alizacion de tigit y pd-1 mediante el uso de compuestos de 1,2,4-oxadiazol. | |
| PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
| NZ746906A (en) | Oxaborole esters and uses thereof |